Search clinical trials for: CARE T cells

Total 24024 results

Chinese PLA General Hospital

Unknown

Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Beijing Immunochina Medical Science & Technology...
Peking University People's Hospital

Not yet recruiting

INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia

Leukemia, B-cell
Weijia Fang, MD
Chongqing Precision Biotech Co., Ltd

Recruiting

A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Renal Cell Carcinoma | Ovarian Cancer | Cervix Cancer | Advanced Solid Tumor | Metastatic Tumor

China
Chongqing Precision Biotech Co., Ltd

Recruiting

A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Renal Cell Carcinoma | Ovarian Cancer | Cervix Cancer | Advanced Solid Tumor | Metastatic Tumor

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer

Renal Cell Carcinoma | Advanced Cancer | Metastatic Tumor

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors

Stomach Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Recurrent Cancer | Metastatic Tumor

China
Weijia Fang, MD
Chongqing Precision Biotech Co., Ltd

Recruiting

A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors

Stomach Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Recurrent Cancer | Metastatic Tumor

China
PeproMene Bio, Inc.
City of Hope Medical Center

Recruiting

BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

United States
CARsgen Therapeutics Co., Ltd.
RenJi Hospital; First Affiliated Hospital of Zhejiang University

Completed

Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed B-cell Non-Hodgkin Lymphoma

China
First Affiliated Hospital of Zhejiang University

Unknown

An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection

Diffuse Large B Cell Lymphoma

China
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | Prolymphocytic Leukemia and other conditions

China
National Institute of Allergy and Infectious Diseases...
University of Pennsylvania Clinical Cell and Vaccine Production Facility...

Not yet recruiting

CAR-T Cell Therapy for Desensitization in Kidney Transplantation

Kidney Failure | End Stage Renal Failure on Dialysis | Kidney Transplant

United States
Ruijin Hospital
Shanghai Essight Bio Co.,Ltd

Recruiting

TCR-T Cells in the Treatment of Advanced Pancreatic Cancer (GB3010-02)

Pancreatic Cancer

China
Cellular Biomedicine Group Ltd.

Recruiting

A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
The Republican Research and Practical Center for...
Belarusian State Medical University

Enrolling by invitation

Study of Leukocyte Immunophenotype and the Lipid Transport System as Predictive Biomarkers of Severe Bacterial Infections

Sepsis | Pneumonia, Bacterial | Infective Endocarditis

Belarus
First Affiliated Hospital Xi'an Jiaotong University
Eureka Therapeutics Inc.

Unknown

ET190L1-ARTEMIS™ T Cells in Relapsed, Refractory B Cell Leukemia and Lymphoma

CD19+ Lymphoma, B-Cell | CD19+ Leukemia, B-Cell

China
Arcellx, Inc.

Recruiting

Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Shenzhen Geno-Immune Medical Institute
The Seventh Affiliated Hospital of Sun Yat-sen University; Shenzhen Children... and other collaborators

Recruiting

PSMA-specific CAR-T Cell Therapy

PSMA Positive Tumors or Tumor Tissues

China
Beijing 302 Hospital
Lion TCR Pte. Ltd.

Recruiting

TCR-Redirected T Cells Therapy in Patient With HBV Related HCC

Hepatocellular Carcinoma

China
Memorial Sloan Kettering Cancer Center

Recruiting

Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

CMV Infection | Persistent CMV Viremia

United States
Baylor College of Medicine
Harris County Hospital District; The Methodist Hospital Research Institute; Center... and other collaborators

Active, not recruiting

TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer (TACTOPS)

Pancreatic Cancer

United States
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Completed

CMV-TCR-T Cells for CM Virus Infection After HSCT

CMV Infection or Reactivation After Allogenic HSCT

China
AlloVir
Baylor College of Medicine; The Methodist Hospital Research Institute; Center...

Completed

Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant (CHARMS)

Infection

United States
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients (ENSIGN)

B-cell Acute Lymphoblastic Leukemia | Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia

United States
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.; Chengdu Military...

Unknown

CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies

B Cell Lymphoma | B Cell Leukemia

China
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Completed

Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts (ETNA)

Epstein-Barr Virus Infections

United States
Beijing Yongtai Ruike Biotechnology Company Ltd

Recruiting

CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL

Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma

Liver Carcinoma | Hepatic Cell Carcinoma

China
Chongqing Precision Biotech Co., Ltd
Zhejiang University

Recruiting

A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors

Breast Cancer | Gastric Cancer | Colorectal Cancer | Bile Duct Cancer | Non-small Cell Lung Cancer | Pancreas Cancer | Esophagus Cancer

China
Chinese PLA General Hospital
UTC Therapeutics Inc.

Recruiting

CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors

Solid Tumor, Adult

China
Chinese PLA General Hospital
UTC Therapeutics Inc.

Recruiting

CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma

Lymphoma

China
920th Hospital of Joint Logistics Support Force...

Withdrawn

A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL

T-lymphoblastic Lymphoma | T-cell Acute Lymphoblastic Leukemia

China
Wuhan Union Hospital, China
Shanghai Cell Therapy Group Co.,Ltd

Unknown

αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors

Non-small-cell Lung Cancer | Mesothelioma

China
Chinese PLA General Hospital

Unknown

Study of PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning of PC in Mesothelin Positive Multiple Solid Tumors

Solid Tumor, Adult

China
Beijing YouAn Hospital
Beijing Gene Key Life Technology Co., Ltd.

Recruiting

Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy

Hepatocellular Carcinoma

China
Luminary Therapeutics
The Cleveland Clinic; Case Western Reserve University

Recruiting

LMY-920 for Treatment of Relapsed or Refractory Myeloma (LMY-920-002)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

United States
Ruijin Hospital
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Unknown

Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma

Lymphoma

China
Chinese PLA General Hospital

Recruiting

Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT

EBV Infection After Allogenic HSCT

China
Chinese PLA General Hospital

Recruiting

CMV-TCR-T Cells for CMV Infection After Allogenic HSCT

CMV Infection After Allogenic HSCT

China
NexImmune Inc.

Suspended

Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma

Relapsed Refractory Multiple Myeloma

United States
University of Pennsylvania

Completed

Autologous CD4 T-Cells in HIV (C34-CXCR4)

Hiv

United States
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Completed

EBV-TCR-T Cells for EB Virus Infection After HSCT

EBV Emia and EBV Positive PTLD After Allogenic HSCT

China
Memorial Sloan Kettering Cancer Center
Atara Biotherapeutics

Completed

Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation

Leukemia | Myelodysplastic Syndrome

United States
Memorial Sloan Kettering Cancer Center

Withdrawn

Safety and Effectiveness of EBV-specific Cytotoxic T Cells for the Treatment for EBV Lymphomas or Other EBV-associated Malignancies

EBV Lymphomas | EBV-associated Malignancies
920th Hospital of Joint Logistics Support Force...

Recruiting

A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies

B-Cell Leukemia | B-Cell Lymphoma | B-cell Tumors

China
CARsgen Therapeutics Co., Ltd.
Fudan University

Recruiting

A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer

Pancreatic Cancer

China
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma

Non-Hodgkin Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory

United States
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Terminated

A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma

Lymphoma, B-Cell

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Withdrawn

Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia

Refractory B Acute Lymphoblastic Leukemia | Relapse B Acute Lymphoblastic Leukemia

China
The First Affiliated Hospital of Guangdong Pharmaceutical...
University of Technology, Sydney; Guangzhou Anjie Biomedical Technology Co....

Unknown

Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC

Non-small Cell Lung Cancer | Lung Neoplasm Malignant

China

Search clinical trials for: CARE T cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations